CVKD - מחיר למכירות Cadrenal Therapeutics Inc.

Cadrenal Therapeutics (CVKD) is developing an R&D model, planning to collect royalties from distributors following the creation of anticoagulants. The revenue valuation metric provided by GURU.Markets demonstrates price dynamics, where the mark serves as the current indicator. The team consists of specialized nephrology experts. Business protection relies on tecarfarin patents, the success of which depends on FDA approval.

The P/S ratio compares the total market value of a business to its annual revenue, allowing for an assessment of revenue generation efficiency. Low values often indicate an undervalued asset, while inflated figures suggest excessive market expectations. By analyzing the current P/S ratio, an investor can determine whether the capitalization is fair. For Cadrenal Therapeutics (CVKD), this metric reflects the market's bet on the commercial success of its safe anticoagulant for nephrology.